Clinical pharmacology consultation and outcomes associated with pregnancy exposure to FDA X Drugs

Clinical pharmacology consultation and outcomes associated with pregnancy exposure to FDA X Drugs

Results In pregnancies with available outcomes, the most frequently FDA-X prescribed drugs were oral contraceptives (53%), followed by paroxetin (21%), medroxiprogesterone (8%), retinoids (7%), warfarin (4%), methotrexate, statins, ribavirin, ulipristal-acetate, and radioactive iodine.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical therapeutics 2015-08, Vol.37 (8), p.e14-e15
Hauptverfasser: Erdeljic Turk, V, Francetic, I, Makar Ausperger, K, Likic, R, Radacic-Aumiler, M
Format: Artikel
Sprache:eng
Schlagworte:
Abortion
Birth weight
Drugs
Health risk assessment
Internal Medicine
Medical Education
Pregnancy
Women
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Results In pregnancies with available outcomes, the most frequently FDA-X prescribed drugs were oral contraceptives (53%), followed by paroxetin (21%), medroxiprogesterone (8%), retinoids (7%), warfarin (4%), methotrexate, statins, ribavirin, ulipristal-acetate, and radioactive iodine.
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2015.05.051